Mountaineer Biomarker Study: A Phase II, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HET2+ Metastatic Colorectal Cancer.
Research Grant
Administered By
Duke Cancer Institute
Awarded By
Seattle Genetics, Inc
Start Date
April 7, 2020
End Date
April 30, 2025
Administered By
Duke Cancer Institute
Awarded By
Seattle Genetics, Inc
Start Date
April 7, 2020
End Date
April 30, 2025